NCT01230801已完成1 期
A Phase 1/2 Open-label Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamic and Preliminary Efficacy of BMN 701 (GILT-tagged Recombinant Human GAA) in Patients With Late-onset Pompe Disease
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 22
- 试验地点
- 10
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
A Phase 1/2, open-label, multicenter, multiple dose escalation study of BMN 701 administered by intravenous infusion every 2 weeks over a 24-week treatment period to patients with late-onset Pompe disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 13 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has been diagnosed with Pompe Disease prior to or during the screening period based on 2 GAA gene mutations and either: endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed in cultured skin fibroblasts -or- endogenous GAA activity <75% of the lower limit of the normal adult range reported by the testing laboratory, as assessed by dried blood spot or whole blood assay;
- •Patient is male or female and 13 years of age or older at the time of enrollment in the study;
- •Sexually active patients must be willing to use an acceptable method of contraception while participating in the study and for at least 4 months following the last dose of BMN 701;
- •If patient is female and not considered to be of childbearing potential, she is at least 2 years post-menopausal or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy;
- •If patient is female and of childbearing potential, she has negative urine pregnancy tests during the Screening Period and at the Baseline visit and be willing to have additional pregnancy tests during the study;
- •Patient has ≥30% predicted upright FVC and either <80% predicted upright FVC, or >10% reduction in supine FVC compared to upright FVC during the Screening Period;
- •Patient is naïve to Enzyme Replacement Therapy (ERT) with rhGAA;
- •Patient must be able to ambulate at least 40 meters (131.2 feet) on the 6MWT conducted at the Screening visit (use of assistive devices such as walker, cane, or crutches, is permitted); and
- •If subject was female, she was not lactating
排除标准
- •Patient has a history of diabetes or other disease known to cause hypoglycemia and is currently receiving, or might anticipate receiving, hypoglycemic agents during the course of the study;
- •Patient has been on any immunosuppressive medication other than glucocorticosteroids within 1 year prior to enrollment into this study;
- •Patient requires invasive ventilatory assistance at the time of enrollment into the study;
- •Patient has received any investigational medication within 30 days prior to the first dose of study drug or is scheduled to receive any investigational drug other than BMN 701 during the course of the study;
- •Patient has previously been admitted to the study;
- •Patient is breastfeeding at screening or planning to become pregnant (self or partner) at any time during the study;
- •Patient has a medical condition or extenuating circumstance that, in the opinion of the Investigator, might compromise the patient's ability to comply with the protocol requirements or compromise the patient's well being or safety;
- •Patient has any condition that, in the view of the Investigator, places the patient at high risk of poor treatment compliance or of not completing the study.
研究组 & 干预措施
BMN 701
Experimental
IV infusion
干预措施: BMN 701 (Biological)
结局指标
主要结局
Number of Participants With Adverse Events
时间窗: 24 weeks
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
次要结局
- Change From Baseline in Six Minutes Walk Test(Baseline up to 24 weeks)
研究者
研究点 (10)
Loading locations...
相似试验
进行中（未招募）
1 期
A Gene Therapy Study of BMN 331 in Subjects With Hereditary AngioedemaHereditary AngioedemaHAENCT05121376BioMarin Pharmaceutical44
进行中（未招募）
1 期
A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMN 351 in Participants With Duchenne Muscular DystrophyDuchenne Muscular DystrophyNCT06280209BioMarin Pharmaceutical18
终止
2 期
Extension Study for Patients Who Have Participated in a BMN 701 StudyPompe DiseaseNCT01435772BioMarin Pharmaceutical21
已完成
1 期
A Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Intracerebroventricular BMN 190 in Patients With Late-Infantile Neuronal Ceroid Lipofuscinosis (CLN2) DiseaseJansky-Bielschowsky DiseaseBatten DiseaseLate-Infantile Neuronal Ceroid Lipofuscinosis Type 2CLN2 DiseaseNCT01907087BioMarin Pharmaceutical24
已完成
1 期
Study of VB10.NEO in Combination With Atezolizumab in Solid TumorsSolid Tumors, AdultNCT05018273Nykode Therapeutics ASA26